BACKGROUND: VCL-CB01, a candidate cytomegalovirus (CMV) DNA vaccine that contains plasmids encoding CMV phosphoprotein 65 (pp65) and glycoprotein B (gB) to induce cellular and humoral immune responses and that is formulated with poloxamer CRL1005 and benzalkonium chloride to enhance immune responses, was evaluated in a phase 1 clinical trial. METHODS: VCL-CB01 was evaluated in 44 healthy adult subjects (22 CMV seronegative and 22 CMV seropositive) 18-43 years old. Thirty-two subjects received 1- or 5-mg doses of vaccine on a 0-, 2-, and 8-week schedule, and 12 subjects received 5-mg doses of vaccine on a 0-, 3-, 7-, and 28-day schedule. RESULTS: Overall, the vaccine was well tolerated, with no serious adverse events. Local reactions included mild to moderate injection site pain and tenderness, induration, and erythema. Systemic reactions included mild to moderate malaise and myalgia. All reactions resolved without sequelae. Through week 16 of the study, immunogenicity, as measured by enzyme-linked immunosorbant assay and/or ex vivo interferon (IFN)-gamma enzyme-linked immunospot assay, was documented in 45.5% of CMV-seronegative subjects and in 25.0% of CMV-seropositive subjects who received the full vaccine series, and 68.1% of CMV-seronegative subjects had memory IFN-gamma T cell responses at week 32. CONCLUSION: The safety and immunogenicity data from this trial support further evaluation of VCL-CB01.
BACKGROUND: VCL-CB01, a candidate cytomegalovirus (CMV) DNA vaccine that contains plasmids encoding CMV phosphoprotein 65 (pp65) and glycoprotein B (gB) to induce cellular and humoral immune responses and that is formulated with poloxamer CRL1005 and benzalkonium chloride to enhance immune responses, was evaluated in a phase 1 clinical trial. METHODS: VCL-CB01 was evaluated in 44 healthy adult subjects (22 CMV seronegative and 22 CMV seropositive) 18-43 years old. Thirty-two subjects received 1- or 5-mg doses of vaccine on a 0-, 2-, and 8-week schedule, and 12 subjects received 5-mg doses of vaccine on a 0-, 3-, 7-, and 28-day schedule. RESULTS: Overall, the vaccine was well tolerated, with no serious adverse events. Local reactions included mild to moderate injection site pain and tenderness, induration, and erythema. Systemic reactions included mild to moderate malaise and myalgia. All reactions resolved without sequelae. Through week 16 of the study, immunogenicity, as measured by enzyme-linked immunosorbant assay and/or ex vivo interferon (IFN)-gamma enzyme-linked immunospot assay, was documented in 45.5% of CMV-seronegative subjects and in 25.0% of CMV-seropositive subjects who received the full vaccine series, and 68.1% of CMV-seronegative subjects had memory IFN-gamma T cell responses at week 32. CONCLUSION: The safety and immunogenicity data from this trial support further evaluation of VCL-CB01.
Authors: S A Plotkin; R Higgins; J B Kurtz; P J Morris; D A Campbell; T C Shope; S A Spector; W M Dankner Journal: Transplantation Date: 1994-12-15 Impact factor: 4.939
Authors: S P Adler; S A Plotkin; E Gonczol; M Cadoz; C Meric; J B Wang; P Dellamonica; A M Best; J Zahradnik; S Pincus; K Berencsi; W I Cox; Z Gyulai Journal: J Infect Dis Date: 1999-09 Impact factor: 5.226
Authors: S Stagno; R F Pass; G Cloud; W J Britt; R E Henderson; P D Walton; D A Veren; F Page; C A Alford Journal: JAMA Date: 1986-10-10 Impact factor: 56.272
Authors: Christian Junghanss; Michael Boeckh; Rachel A Carter; Brenda M Sandmaier; Michael B Maris; David G Maloney; Thomas Chauncey; Peter A McSweeney; Marie-Térèse Little; Lawrence Corey; Rainer Storb Journal: Blood Date: 2002-03-15 Impact factor: 22.113
Authors: Jane R Deayton; Caroline A Prof Sabin; Margaret A Johnson; Vincent C Emery; Pauline Wilson; Paul D Griffiths Journal: Lancet Date: 2004-06-26 Impact factor: 79.321
Authors: E A Walter; P D Greenberg; M J Gilbert; R J Finch; K S Watanabe; E D Thomas; S R Riddell Journal: N Engl J Med Date: 1995-10-19 Impact factor: 91.245
Authors: Andrew W Sylwester; Bridget L Mitchell; John B Edgar; Cara Taormina; Christian Pelte; Franziska Ruchti; Paul R Sleath; Kenneth H Grabstein; Nancy A Hosken; Florian Kern; Jay A Nelson; Louis J Picker Journal: J Exp Med Date: 2005-09-05 Impact factor: 14.307
Authors: Mark Cobbold; Naeem Khan; Batoul Pourgheysari; Sudhir Tauro; Dorothy McDonald; Husam Osman; Mario Assenmacher; Lucinda Billingham; Colin Steward; Charles Crawley; Eduardo Olavarria; John Goldman; Ronjon Chakraverty; Premini Mahendra; Charles Craddock; Paul A H Moss Journal: J Exp Med Date: 2005-08-01 Impact factor: 14.307
Authors: Corinna La Rosa; Jeff Longmate; Simon F Lacey; Teodora Kaltcheva; Rahul Sharan; Denise Marsano; Peter Kwon; Jennifer Drake; Brenda Williams; Sharon Denison; Suenell Broyer; Larry Couture; Ryotaro Nakamura; Sanjeet Dadwal; Morris I Kelsey; Arthur M Krieg; Don J Diamond; John A Zaia Journal: J Infect Dis Date: 2012-03-07 Impact factor: 5.226